Antisense Therapeutics Ltd. | Key People and Executives
Mark Diamond
Chief Executive Officer, Executive Director & MD
Robert William Moses
Independent Non-Executive Chairman
Gary W. Pace
Independent Non-Executive Director
William Alden Goolsbee
Independent Non-Executive Director
Graham F. Mitchell
Independent Non-Executive Director
Mark Diamond
Chief Executive Officer, Executive Director & MD
Phillip Allen Hains
Chief Financial Officer & Secretary
Nuket Desem
Director-Clinical & Regulatory Affairs
George Tachas
Director-Drug Discovery & Patents
Robert William Moses
Independent Non-Executive Chairman
Gary W. Pace
Independent Non-Executive Director
William Alden Goolsbee
Independent Non-Executive Director
Graham F. Mitchell
Independent Non-Executive Director
| Address |
6-8 Wallace Avenue
Toorak Victoria (VIC) 3142
Australia
|
|
Employees
|
- |
| Website |
http://www.antisense.com.au |
| Updated |
07/08/2019 |
| Antisense Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. It operates through the ATL1102, and ATL1103 segments. The ATL1102 segment represents the second generation antisense inhibitor of CD49d, the alpha subunit of very late antigen-four. |
